Abstract:BACKGROUND:Although a number of clinical and preclinical studies have demonstrated analgesic effects of cannabinoid treatments, there are also instances when cannabinoids have had no effect or even exacerbated pain. The observed pro-nociceptive effects appear to be due to cannabinoid-induced disinhibition of afferent synaptic input to nociceptive circuits. To better understand how cannabinoid-mediated plasticity can have both pro- and anti-nociceptive effects, we examined the possibility that cannabinoids differentially modulate nociceptive vs. non-nociceptive synapses onto a shared postsynaptic target. These experiments were carried out in the central nervous system (CNS) of the medicinal leech, in which it is possible to intracellularly record from presynaptic nociceptive (N-cell) or pressure-sensitive (P-cell) neurons and their shared postsynaptic targets.RESULTS:The endocannabinoid 2-arachidonoyl glycerol (2AG) elicited significant long-lasting depression in nociceptive (N-cell) synapses. However, non-nociceptive (P-cell) synapses were potentiated following 2AG treatment. 2AG-induced potentiation of non-nociceptive synapses was blocked by the TRPV antagonist SB366791, suggesting involvement of the same TRPV-like receptor that has already been shown to mediate endocannabinoid-dependent depression in nociceptive inputs. Treatment with the GABA receptor antagonist bicuculline also blocked 2AG-induced potentiation, consistent with the idea that increased synaptic signaling was the result of endocannabinoid-mediated disinhibition. Interestingly, while bicuculline by itself increased non-nociceptive synaptic transmission, nociceptive synapses were depressed by this GABA receptor antagonist indicating that nociceptive synapses were actually excited by GABAergic input. Consistent with these observations, GABA application depolarized the nociceptive afferent and hyperpolarized the non-nociceptive afferent.CONCLUSIONS:These findings show that endocannabinoids can differentially modulate nociceptive vs. non-nociceptive synapses and that GABAergic regulation of these synapses plays an important role in determining whether endocannabinoids have a potentiating or depressing effect.

Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.

Correction: Divergent Modulation of Pain and Anxiety by GABAergic Neurons in the Ventrolateral Periaqueductal Gray and Dorsal Raphe.

Cannabinoid Potentiation of Glycine Receptors Contributes to Cannabis-Induced Analgesia.

Involvement of Glycine Receptor Α1 Subunits in Cannabinoid-Induced Analgesia.

The Cannabinoid Dehydroxylcannabidiol Suppresses Neuropathic Pain by Upregulating a Spinal Glycine Receptor-Mediated Compensation Mechanism

Mesoporous Silica Particles As a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

Differential Modulation of Nociceptive Versus Non-Nociceptive Synapses by Endocannabinoids.

Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia

Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model

Physiological profiling of cannabidiol reveals profound inhibition of sensory neurons

Divergent modulation of pain and anxiety by GABAergic neurons in the ventrolateral periaqueductal gray and dorsal raphe

Cannabidiol alleviates neuroinflammation and attenuates neuropathic pain via targeting FKBP5

Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia

Functionally-selective inhibition of threshold sodium currents and excitability in dorsal root ganglion neurons by cannabinol

Activation of µ-δ opioid receptor heteromers inhibits neuropathic pain behavior in rodents.

Negative allosteric modulation of cannabinoid CB receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination

Differential regulation of Cav 3.2 and Cav 2.2 calcium channels by CB1 receptors and cannabidiol

Transcriptomic Profiling in Mice With CB1 receptor Deletion in Primary Sensory Neurons Suggests New Analgesic Targets for Neuropathic Pain

New Insights in Cannabinoid Receptor Structure and Signaling

Cannabinoid receptor-1 antagonist inhibits morphine tolerance in rats with inflammatory pain